The S&P 500 gained 0.1% on Thursday, July 24, 2025, notching an all-time closing high for the fourth straight day following ...

West Pharmaceutical Services, Inc.'s Q2 results highlight growth driven by GLP-1 drugs and high-value products. Click for WST ...

Q2 2025 Earnings Call Transcript July 24, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported EPS ...

West Pharmaceutical Services is expected to announce its second-quarter results later this month, with analysts projecting a marginal drop in its bottom line.

Key Points - Adjusted EPS was $1.84 in Q2 FY2025, beating the $1.51 estimate by 21.9%, and GAAP revenue exceeded expectations by $40.4 million. Proprietary Products sales rose 10.7%, driven by strong ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Brasada Capital Management, an investment management company, released its Q2 2025 investor letter. A copy of the letter can be downloaded here. This year’s financial markets have been highly volatile ...

Alabama, Indiana, Missouri, Tennessee, Texas and Utah also have scheduled executions for later this year.     Executions have been carried out this year in Alabama, Arizona, Florida, Indiana, ...

West Pharmaceutical Services, Inc. (NYSE:WST) shares are surging Thursday after the injectable pharmaceutical packaging and ...

Discover West Pharma's robust Q2 2025 performance with 6.8% organic sales growth! Learn about raised guidance, high-margin gains, & GLP-1 market ...

West Pharmaceutical Services, Inc. (NYSE:WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products.

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday.